Back to Healio
Saved
BySteven Lome, MD

ASCERT Trial

BySteven Lome, MD

Trial Details

Acronym: American College of Cardiology (ACC) Foundation/STS Collaboration on the Comparative Effectiveness of Revascularization Strategies Trial

Purpose: Evaluated percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG)

Format: Nonrandomized, observational

Treatment Group 1: PCI

Treatment Group 2: CABG

Number of Patients: 1,943,653

Exclusion Criteria:

  • Single-vessel disease
  • Left main coronary artery disease
  • Cardiogenic shock
  • Myocardial infarction
  • Insertion of an intraaortic balloon pump before either procedure
  • CABG or valve surgery or PCI within 180 days

Primary Endpoint: all-cause mortality

Follow-up: mean 2.72

Summary:

The ASCERT trial found that CABG reduced all-cause mortality at 4 years compared to PCI. At 1 year there was no difference in all-cause mortality.

Original Publication:

Weintraub WS, et al. N Engl J Med. 2012;doi: 10.1056/NEJMoa1110717.